Holoxan (Ifosfamide)

Holoxan (ifosfamide) is indicated for use in adult patients with certain types of cancer where DNA‑targeting chemotherapy is appropriate. The drug may be used alone or as part of combination regimens, often in conjunction with mesna to reduce urotoxic risk.

• Soft tissue sarcoma, including extremity and retroperitoneal disease
• Testicular non‑seminomatous germ cell tumors
• Advanced or metastatic solid tumors when combined with other chemotherapeutic agents
• Selected pediatric solid tumors under specialist supervision
• Refractory malignant germ cell tumors of the ovary or other sites

• Ifosfamide is a nitrogen‑mustard alkylating agent that enters cells and undergoes hepatic activation to form reactive isophosphoramide mustard. The metabolite covalently binds to nucleophilic sites on DNA, creating intra‑ and interstrand cross‑links that impede DNA replication and transcription. This damage triggers cell‑cycle arrest and apoptosis, preferentially affecting rapidly dividing tumor cells. The alkylation also interferes with DNA repair enzymes and can generate reactive oxygen species that further contribute to cytotoxicity.

Like most chemotherapy agents, Holoxan can cause a range of adverse reactions that vary in frequency and severity.

Common

• Nausea, vomiting, and loss of appetite
• Fatigue and generalized weakness
• Low white blood cell count (neutropenia) leading to infection risk
• Mild to moderate urinary irritation or hematuria

Serious

• Severe neutropenia or febrile neutropenia
• Hemorrhagic cystitis, especially without adequate mesna protection
• Renal toxicity manifested by elevated creatinine or reduced glomerular filtration

Healthcare providers should evaluate patient history and monitor clinical parameters before and during treatment with Holoxan to minimize risks.

• Assess baseline renal function; dose adjustments may be required for impaired kidneys
• Verify adequate hydration and consider mesna prophylaxis to protect the bladder
• Review complete blood counts regularly to detect neutropenia or thrombocytopenia
• Avoid use in patients with known hypersensitivity to ifosfamide or related nitrogen‑mustard compounds
• Counsel women of child‑bearing potential about contraception, as fetal effects are unknown
• Monitor liver enzymes because hepatic metabolism is essential for drug activation

Ifosfamide may interact with other medicines, affecting its efficacy or increasing toxicity.

Avoid

• Concomitant use of nephrotoxic agents such as cisplatin or aminoglycosides without close monitoring
• Drugs that strongly inhibit CYP3A4, which can alter ifosfamide activation

Use with caution

• Other myelosuppressive chemotherapy agents, which may exacerbate bone‑marrow suppression
• Anticoagulants, because thrombocytopenia can increase bleeding risk
• Live vaccines, due to potential immunosuppression
• Radiotherapy to the same treatment field, which may heighten tissue toxicity